Company: INMB
Filing Date: 2025-04-09
Form Type: 8-K
Source: 0001213900-25-030129
Chunk: 0

Company: Inmune Bio, Inc.
Filing Date: 2025-04-09
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01. Regulation FD Disclosure.

On April 3, 2025, INmune
Bio Inc. (the “ Company”) presented a poster (the “ Poster Presentation”) at the annual International Conference
on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders taking place in Vienna, Austria. The Poster Presentation
details the demographics and biomarker status of patients at the time of enrollment in the Company’s MINDFul Phase II blinded, randomized
trial in patients with early Alzheimer’s disease and biomarkers of inflammation.

The Poster Presentation
is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this
Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is furnished and shall not be deemed to be “filed” for the purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities
of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference
into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of
this Current Report on Form 8-K, regardless of any general incorporation language in any such filing.

Item 9.01 Financial statements and Exhibits